These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 6199608)

  • 21. Propofol does not induce pulmonary dysfunction in stressed endotoxic pigs receiving Intralipid.
    Ziser A; Strickland RA; Murray MJ
    Crit Care Med; 2003 Jul; 31(7):2029-33. PubMed ID: 12847400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic high-dose N(omega)-monomethyl-L-arginine prevents the late cardiac dysfunction associated with lethal tumor necrosis factor-alpha challenge in dogs.
    Sevransky J; Vandivier RW; Gerstenberger E; Correa R; Ferantz V; Banks SM; Danner RL; Eichacker PQ; Natanson C
    Shock; 2005 Mar; 23(3):281-8. PubMed ID: 15718929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different response of the rat left and right heart to norepinephrine.
    Irlbeck M; Muhling O; Iwai T; Zimmer HG
    Cardiovasc Res; 1996 Jan; 31(1):157-62. PubMed ID: 8849601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
    Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hemodynamic effects of disopyramide on postischemic and normal myocardium].
    Hoffmeister HM; Hörmann HP; Beyer M; Seipel L
    Klin Wochenschr; 1990 Dec; 68(23):1178-82. PubMed ID: 2280581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
    Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A
    Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
    Landmark K; Bredesen JE; Thaulow E; Simonsen S; Amlie JP
    Eur J Clin Pharmacol; 1981 Feb; 19(3):187-92. PubMed ID: 7215416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disopyramide pharmacokinetics in patients with acute myocardial infarction.
    Pentikäinen PJ; Huikuri H; Jounela AJ; Wilen G
    Eur J Clin Pharmacol; 1985; 28(1):45-51. PubMed ID: 3987785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemodynamic effects of disopyramide using a new model of intravenous administration.
    Bonde J; Pedersen LE; Angelo HR; Svendsen TL; Trap-Jensen J; Graudal NA; Kampmann JP
    Pharmacol Toxicol; 1987 Mar; 60(3):179-83. PubMed ID: 3588512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma concentrations and hemodynamic effects of nifedipine: a study in anesthetized dogs.
    Hamann SR; McAllister RG
    J Cardiovasc Pharmacol; 1983; 5(6):920-7. PubMed ID: 6196563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of erythropoietin in intact and anephric dogs.
    Fu JS; Lertora JJ; Brookins J; Rice JC; Fisher JW
    J Lab Clin Med; 1988 Jun; 111(6):669-76. PubMed ID: 3373111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ammonia kinetics in eight patients with liver disease and in dogs.
    de Bruijn KM; Gips CH
    Hepatogastroenterology; 1987 Feb; 34(1):1-4. PubMed ID: 3570136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
    Bryson SM; Whiting B; Lawrence JR
    Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of disopyramide in decreased hepatic function.
    Bonde J; Graudal NA; Pedersen LE; Balsløv S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1986; 31(1):73-7. PubMed ID: 3780831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The stereoselective disposition of disopyramide in the dog.
    Giacomini KM; Giacomini JC; Swezey SE; Harrison DC; Nelson WL; Burke TR; Blaschke TF
    J Cardiovasc Pharmacol; 1980; 2(6):825-32. PubMed ID: 6160331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disopyramide pharmacokinetics during recovery from myocardial infarction.
    Bryson SM; Cairns CJ; Whiting B
    Br J Clin Pharmacol; 1982 Mar; 13(3):417-21. PubMed ID: 7059444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
    Lima JJ; Haughey DB; Leier CV
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias.
    Chiba K; Koike K; Nakamoto M; Echizen H; Ishizawa A; Ishizaki T
    Ther Drug Monit; 1992 Apr; 14(2):112-8. PubMed ID: 1585394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis.
    Sevka MJ; Matthews SJ; Nightingale CH; Izard MW; Fieldman A; Chow MS
    Clin Pharmacol Ther; 1981 Mar; 29(3):322-6. PubMed ID: 7471602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.